X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (551) 551
index medicus (494) 494
sphingosine - analogs & derivatives (416) 416
fingolimod hydrochloride (413) 413
multiple sclerosis (369) 369
female (307) 307
fingolimod (302) 302
immunosuppressive agents - therapeutic use (291) 291
male (278) 278
immunosuppressive agents - adverse effects (258) 258
fty720 (226) 226
animals (223) 223
adult (222) 222
propylene glycols - therapeutic use (218) 218
oral fingolimod (202) 202
clinical neurology (201) 201
multiple sclerosis, relapsing-remitting - drug therapy (201) 201
multiple sclerosis - drug therapy (196) 196
sphingosine - therapeutic use (178) 178
middle aged (171) 171
propylene glycols - adverse effects (165) 165
fingolimod hydrochloride - therapeutic use (150) 150
sphingosine - adverse effects (150) 150
fingolimod hydrochloride - adverse effects (133) 133
pharmacology & pharmacy (133) 133
propylene glycols - pharmacology (133) 133
immunosuppressive agents - pharmacology (130) 130
immunosuppressive agents - administration & dosage (126) 126
neurosciences (120) 120
treatment outcome (113) 113
sphingosine - pharmacology (112) 112
neurology (109) 109
mice (97) 97
drug therapy (96) 96
natalizumab (94) 94
propylene glycols - administration & dosage (90) 90
immunology (88) 88
sphingosine 1-phosphate (88) 88
rats (84) 84
administration, oral (80) 80
sphingosine - administration & dosage (79) 79
magnetic resonance imaging (74) 74
relapsing multiple-sclerosis (73) 73
placebo-controlled trial (71) 71
young adult (71) 71
analysis (68) 68
transplantation (68) 68
sphingosine (67) 67
fingolimod hydrochloride - pharmacology (64) 64
research (64) 64
care and treatment (63) 63
multiple-sclerosis (63) 63
safety (63) 63
fingolimod hydrochloride - administration & dosage (62) 62
dosage and administration (59) 59
interferon (59) 59
double-blind (57) 57
lymphocytes (57) 57
receptors, lysosphingolipid - metabolism (54) 54
time factors (53) 53
phosphates (52) 52
disease progression (51) 51
experimental autoimmune encephalomyelitis (51) 51
abridged index medicus (50) 50
surgery (50) 50
medicine & public health (48) 48
article (46) 46
sphingosine-1-phosphate (46) 46
disease models, animal (45) 45
dose-response relationship, drug (45) 45
health aspects (45) 45
recurrence (45) 45
apoptosis (44) 44
medicine, general & internal (44) 44
patients (44) 44
adolescent (43) 43
circulating mature lymphocytes (42) 42
immunologic factors - therapeutic use (42) 42
therapy (42) 42
trial (41) 41
central-nervous-system (40) 40
mice, inbred c57bl (40) 40
natalizumab - therapeutic use (40) 40
clinical trials (39) 39
glatiramer acetate (39) 39
progressive multifocal leukoencephalopathy (39) 39
interferon-beta - therapeutic use (38) 38
aged (37) 37
immunosuppressant (37) 37
lymphocyte egress (37) 37
lymphocyte count (36) 36
efficacy (35) 35
heart rate - drug effects (35) 35
in-vivo (35) 35
antibodies, monoclonal, humanized - therapeutic use (34) 34
disability evaluation (34) 34
drug therapy, combination (34) 34
hemic and lymphatic diseases (33) 33
pharmacology (33) 33
research article (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (678) 678
German (8) 8
Japanese (8) 8
Spanish (8) 8
Chinese (3) 3
French (3) 3
Hungarian (3) 3
Finnish (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2018, Volume 19, Issue 5, pp. 483 - 498
Introduction: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at... 
interferon beta | Multiple sclerosis | ocrelizumab | dimethylfumarate | alemtuzumab | cladribine | fingolimod | teriflunomide | glatiramer acetate | natalizumab | daclizumab | HIGH-YIELD PROCESS | CONTROLLED PHASE-3 | GRANULE CELL NEURONOPATHY | FUMARIC-ACID ESTERS | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | VARICELLA-ZOSTER-VIRUS | INTERFERON-BETA THERAPY | TERM-FOLLOW-UP | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | Alemtuzumab - adverse effects | Neoplasms - etiology | Crotonates - metabolism | Alemtuzumab - metabolism | Humans | Immunosuppressive Agents - therapeutic use | Natalizumab - adverse effects | Natalizumab - metabolism | Interferon-beta - therapeutic use | Interferon-beta - adverse effects | Natalizumab - therapeutic use | Fingolimod Hydrochloride - adverse effects | Fingolimod Hydrochloride - therapeutic use | Toluidines - therapeutic use | Toluidines - metabolism | Toluidines - adverse effects | Fingolimod Hydrochloride - metabolism | Crotonates - therapeutic use | Glatiramer Acetate - adverse effects | Cladribine - metabolism | Interferon-beta - metabolism | Cladribine - therapeutic use | Glatiramer Acetate - therapeutic use | Multiple Sclerosis - pathology | Glatiramer Acetate - metabolism | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Cladribine - adverse effects | Crotonates - adverse effects | Alemtuzumab - therapeutic use | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy
Journal Article
Journal of Neurology, ISSN 0340-5354, 12/2018, Volume 265, Issue 12, pp. 2980 - 2992
Journal Article
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, ISSN 0275-004X, 10/2018, Volume 38, Issue 10, pp. E80 - E81
Journal Article
Drugs, ISSN 0012-6667, 10/2017, Volume 77, Issue 16, pp. 1755 - 1768
Journal Article
Muscle & Nerve, ISSN 0148-639X, 12/2017, Volume 56, Issue 6, pp. 1077 - 1084
Journal Article